Neurocrine Biosciences (NBIX) shares were up 24% ahead of opening bell Wednesday thanks to news from the company that it received FDA approval for its tardive dyskinesia drug.
The company's shares were trading at $51.95 apiece just before market open. This was after a relatively positive trading day Tuesday. Neurocrine shares were up 2.9% during normal trading hours. Tardive dyskinesia is caused by long term use of mental health drugs. It causes patients to experience involuntary facial movements.
Synergy Pharmaceuticalsundefined meanwhile, was also trading positively ahead of market's open. The company's shares were up 5.6% ahead of market's open Wednesday.
This was thanks to news that Synergy was issued three new patents for its flagship product, Trulance, which is used to treat constipation in adults.
Shares were trading at around $4.66 apiece Wednesday. This was after they closed up 1.38% Tuesday.
Organovo (ONVO) shares were sliding the opposite direction ahead of market's open.. The company's shares fell 2.6% ahead of the opening bell on news that its CEO Keith Murphy is stepping down.
The company's shares were sitting at $2.96 at the time of writing.
Taylor Crouch, previously CEO of eStudySite, will take the helm at Organovo as a result.